Pseudomonas aeruginosa bacteremia in patients infected with human immunodeficiency virus type 1

被引:36
作者
Vidal, F
Mensa, J
Martínez, JA
Almela, M
Marco, F
Gatell, JM
Richart, C
Soriano, E
de Anta, MTJ
机构
[1] Univ Rovira & Virgili, Hosp Tarragona JOAN XXIII, Dept Internal Med, Dept Surg & Med,Fac Med & Hlth Sci, E-43007 Tarragona, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, Dept Infect Dis, E-08036 Barcelona, Spain
[3] Univ Barcelona, Hosp Clin Barcelona, Dept Microbiol, E-08036 Barcelona, Spain
关键词
D O I
10.1007/s100960050326
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
A prospective analysis of 43 episodes of Pseudomonas aeruginosa bacteremia in HIV-l-infected subjects was performed and the results compared with the incidence and outcome of Pseudomonas aeruginosa bacteremia in other high-risk patients, such as transplant recipients, leukemia patients, or patients hospitalized in the intensive care unit. The incidence of bacteremia/fungemia as a whole and of gram-negative and Pseudomonas aeruginosa bacteremia in particular was greater in HIV-l-infected subjects than in the unselected general population admitted. In contrast, the incidence of Pseudomonas aeruginosa bacteremia in HIV-l-infected patients did not differ from that in patients with other high-risk conditions. In patients with HIV-1 infection, independent risk factors for presenting Pseudomonas aeruginosa bacteremia were nosocomial origin (OR, 2.7; 95% CI, 1.3-5.7), neutropenia (OR, 2.7; 95% CI, 1.07-6.8), previous treatment with cephalosporins (OR, 3.6; 95% CI, 1.1-11.6), and a CD4+ cell count lower than 50 cells/mm(3) (OR, 3.1; 95% CI, 1.7-8.6). Primary bacteremia and pneumonia were the most common forms of presentation. Fourteen (33%) patients died as a consequence of the bacteremia. The presence of severe sepsis (OR, 17.5; 95% CI, 3.2-68) and the institution of inappropriate definitive antibiotic therapy (OR, 2.7; 95% CI, 1.1-13) were independently associated with a poor outcome. One year after the development of bacteremia, only eight (19%) patients remained alive.
引用
收藏
页码:473 / 477
页数:5
相关论文
共 27 条
[1]  
[Anonymous], M7A2 NCCLS
[2]   PSEUDOMONAS-AERUGINOSA BRONCHOPULMONARY INFECTION IN LATE HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE [J].
BARON, AD ;
HOLLANDER, H .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 148 (04) :992-996
[3]  
BISBE J, 1988, REV INFECT DIS, V10, P629
[4]   APPROACH TO TREATMENT OF THE FEBRILE CANCER-PATIENT WITH LOW-RISK NEUTROPENIA [J].
BUCHANAN, GR .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1993, 7 (05) :919-935
[5]  
Cox DR., 2018, Analysis of Binary Data, DOI [10.1201/9781315137391, DOI 10.1201/9781315137391]
[6]  
Dixon WJ, 1985, BMDP STAT SOFTWARE
[7]   RECOVERY OF PSEUDOMONAS-AERUGINOSA IN RESPIRATORY SPECIMENS FROM HIV-POSITIVE PATIENTS BEING EVALUATED FOR PNEUMOCYSTIS-CARINII PNEUMONIA [J].
DOYLE, RL ;
DOHERTY, JJ ;
ZIMMERMAN, LH .
THORAX, 1995, 50 (05) :548-550
[8]   CLINICAL MANIFESTATIONS AND RISK-FACTORS OF PSEUDOMONAS-AERUGINOSA INFECTION IN PATIENTS WITH AIDS [J].
DROPULIC, LK ;
LESLIE, JM ;
ELDRED, LJ ;
ZENILMAN, J ;
SEARS, CL .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :930-937
[9]  
Fauci A.S., 2015, HARRISONS PRINCIPLES
[10]   GLUCOCORTICOSTEROID THERAPY - MECHANISMS OF ACTION AND CLINICAL CONSIDERATIONS [J].
FAUCI, AS ;
DALE, DC ;
BALOW, JE .
ANNALS OF INTERNAL MEDICINE, 1976, 84 (03) :304-315